Trial Profile

Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JR-441 (Primary)
Indications Mucopolysaccharidosis III
Focus Adverse reactions; First in man
Sponsors JCR Pharmaceuticals

Most Recent Events

14 Feb 2024 According to a JCR Pharmaceuticals media release, trial design of this trial was presented at the 20th Annual WORLDSymposium 2024.
25 Jan 2024 According to a JCR Pharmaceuticals media release, data from this study will be presented at the 20th Annual WORLDSymposium 2024.
13 Nov 2023 According to a JCR Pharmaceuticals media release, the company expect to enroll last patient in H1 of FY2024 and have the one-year readout in H2 of FY2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com